The cubic ternary complex receptor-occupancy model .3. Resurrecting efficacy

被引:140
作者
Weiss, JM
Morgan, PH
Lutz, MW
Kenakin, TP
机构
[1] N CAROLINA STATE UNIV,DEPT STAT,BIOMATH PROGRAM,RALEIGH,NC 27695
[2] GLAXO WELLCOME INC,DEPT RES COMP,RES TRIANGLE PK,NC 27709
[3] GLAXO WELLCOME INC,DEPT CELLULAR BIOCHEM,RES TRIANGLE PK,NC 27709
关键词
D O I
10.1006/jtbi.1996.0139
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Early work in pharmacology characterized the interaction of receptors and ligands in terms of two parameters, affinity and efficacy, an approach we term the bipartite view. A precise formulation of efficacy only exists for very simple pharmacological models. Here we extend the notion of efficacy to models that incorporate receptor activation and G-protein coupling. Using the cubic ternary complex model, we show that efficacy is not purely a property of the ligand-receptor interaction; it also depends upon the distributional details of the receptor species in the native receptor ensemble. This suggests a distinction between what we call potential efficacy (a vector) and realized efficacy (a scalar). To each receptor species in the native receptor ensemble we assign a part-worth utility; taken together these utilities comprise the potential efficacy vector. Realized efficacy is the expectation of these part-worth utilities with respect to the frequency distribution of receptor species in the native receptor ensemble. In the parlance of statistical decision theory, the binding of a ligand to a receptor ensemble is a random prospect and realized efficacy is the utility of this prospect. We explore the implications that our definition of efficacy has for understanding agonism and in assessing the legitimacy of the bipartite view in pharmacology. (C) 1996 Academic Press Limited
引用
收藏
页码:381 / 397
页数:17
相关论文
共 24 条
[1]   OPERATIONAL MODELS OF PHARMACOLOGICAL AGONISM [J].
BLACK, JW ;
LEFF, P .
PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1983, 220 (1219) :141-162
[2]   BIOLOGICAL LEVELS [J].
BUXBAUM, RE .
NATURE, 1995, 373 (6515) :567-568
[3]  
CLARK AJ, 1987, HEFFNERS HDB EXPERIM, V4
[4]  
COLOQUHOUN D, 1987, PERSPECTIVES RECEPTO, P103
[5]  
COSTA T, 1992, MOL PHARMACOL, V41, P549
[7]  
EHLERT FJ, 1985, MOL PHARMACOL, V28, P410
[8]  
Furchgott R., 1966, ADV DRUG RES, V3, P21
[9]   PARTIAL AGONISTS, FULL AGONISTS, ANTAGONISTS - DILEMMAS OF DEFINITION [J].
HOYER, D ;
BODDEKE, HWGM .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (07) :270-275
[10]   TESTING MODELS OF AGONISM FOR G-PROTEIN-COUPLED RECEPTORS [J].
KEEN, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (10) :371-374